Amphetamine-metabolites of deprenyl involved in protection against neurotoxicity induced by MPTP and 2′-methyl-MPTP
The ability of 1-deprenyl to protect against the parkinsonian effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) has been attributed to the inhibition of conversion of MPTP to MPP+ (1-methyl-4-phenylpyridinium) catalyzed by MAO-B. We report here that deprenyl-treatment in mice has an additional neuroprotective element associated with the rapid metabolization of 1-deprenyl to 1-methamphetamine and 1-amphetamine. 1-Methamphetamine and 1-amphetamine inhibit MPP+-uptake into striatal synaptosomes prepared from rats. Post-treatment by 1-deprenyl, 1-methamphetamine, 1-amphetamine (at times when MPTP is no longer present in the striatum of mice) protects against neurotoxicity in C57BL mice by blocking the uptake of MPP+ into dopaminergic neurons, and even against the neurotoxicity induced by 2’CH3-MPTP, which is partly bioactivated by MAO-A. These findings may have clinical implications since deprenyl has recently been found to delay the progression of Parkinson’s disease.
KeywordsDopaminergic Neuron Monoamine Oxidase MPTP Treatment Parkinson Study Group Striatal Level
Unable to display preview. Download preview PDF.
- Chiueh CC, Johannessen JN, Sun JL, Bacon JP, Markey SP (1986) Reversible neuro-toxicity of MPTP in the nigrostriatal dopaminergic system of mice. In: Markey SP, Castagnoli N Jr, Trevor AJ, Kopin IJ (eds) MPTP — a neurotoxin producing a parkinsonian syndrome. Academic Press, New York, pp 473–479.Google Scholar
- Horn AS (1978) Characteristics of neuronal dopamine uptake. In: Roberts PJ (ed) Advances in biochemical psychopharmacology, vol 19. Raven Press, New York, pp 25–34.Google Scholar
- Javitch JA, D’Amato RJ, Strittmatter SM, Snyder SH (1985) Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci USA 82: 2173–2177.PubMedCrossRefGoogle Scholar
- Jonsson G, Sundström E, Nwanze E, Hallman H, Luthman J (1986) Mode of action of MPTP on catecholominergic neurons in the mouse. In: Markey SP, Castagnoli N Jr, Trevor AJ, Kopin IJ (eds) MPTP — a neurotoxin producing a parkinsonian syndrome. Academic Press, New York, pp 253–272.Google Scholar
- Sziráki I, Andrási F, Berzsenyi P, Horváth K, Kardos V, Patthy M, Pátfalusi M, Szabó G, Szabó H (1990) Pharmacological and neurochemical properties of GYKI-52 895, a new selective dopamine uptake inhibitor. In: Abstracts of Dopamine’ 90. Satellite Meeting of the XIth International Congress of Pharmacology, Como, Italy, July 8–11, 1990, p 36.Google Scholar
- Sziráki I, Kardos V, Patthy M, Pátfalusi M, Budai Gy (1993) Methamphetamine protects against MPTP-neurotoxicity in mice C57BL. Eur J Pharmacol (submitted).Google Scholar